RegulationAccelerated Approval (United States), Breakthrough Therapy (China), Orphan Drug (South Korea), Priority Review (United States), Breakthrough Therapy (United States)

Structure/Sequence

Sequence Code 143885L

Source: *****

Sequence Code 13387733H

Source: *****

Sequence Code 13387743H

Source: *****

Sequence Code 13387747L

Source: *****

Clinical Trials associated with Amivantamab-VMJM

NCT06855849

/ Not yet recruitingPhase 2IIT

An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

This trial is a multicenter, single arm study of efficacy of amivantamab in combination with FOLFIRI in RAS/BRAF wild-type advanced colorectal cancer patients progressed prior treatment including oxaliplatin based chemotherapy. This trial will be conducted by Severance Hospital that is responsible for the project management of the trial. Patient recruitment will take at 3 institutions.
Participants will be treated for up to 24 cycles (approximately 2 years) after initiation of treatment with intravenous 1050mg(BW<80kg) or 1400mg(BW≥80kg) of amivantamab every 4 weeks in combination with FOLFIRI. FOLFIRI includes folic acid, 5-FU and irinotecan. FOLFIRI will be administered intravenously with folic acid 400 mg/m², 5-FU 2400 mg/m², and irinotecan 180 mg/m² every 2 weeks. This study will use ORR based on RECIST 1.1 criteria as the primary endpoint and the tumor assessment will be done every 8 weeks. Secondary endpoints are DCR, PFS, OS, and safeties. Exploratory biomarkers in tumor tissue and ctDNA in blood will be investigated in both pre-treatment and post-treatment periods.

Start Date01 May 2025

Sponsor / Collaborator

Yonsei University

ChiCTR2500100101

/ SuspendedPhase 2IIT

Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start Date14 Apr 2025

Sponsor / Collaborator

Shanghai East Hospital

NCT06816992

/ RecruitingPhase 1

Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.

Start Date27 Feb 2025

Sponsor / Collaborator

Oric Pharmaceuticals, Inc.

[+1]

100 Clinical Results associated with Amivantamab-VMJM

100 Translational Medicine associated with Amivantamab-VMJM

100 Patents (Medical) associated with Amivantamab-VMJM

176

Literatures (Medical) associated with Amivantamab-VMJM

01 Dec 2025·Current Neurology and Neuroscience Reports

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review

Review

Author: Gowda, Maya ; Camacho, Alejandra M ; Ranjan, Tulika ; Ahluwalia, Manmeet S ; Podder, Vivek

PURPOSE OF REVIEW:

Advancements in precision medicine have shifted the treatment paradigm of brain metastases (BM) from non-small cell lung cancer (NSCLC), breast cancer, and melanoma, especially through targeted therapies focused on specific molecular drivers. These novel agents have improved outcomes by overcoming challenges posed by the blood-brain barrier (BBB) and resistance mechanisms, enabling more effective treatment of BM.

RECENT FINDINGS:

In NSCLC, therapies such as osimertinib have improved efficacy in treating EGFR-mutant BM, with emerging combinations such as amivantamab and lazertinib offering promising alternatives for patients resistant to frontline therapies. In HER2-positive breast cancer, significant advancements with tucatinib and trastuzumab deruxtecan (T-DXd) have transformed the treatment landscape, achieving improved survival and intracranial control in patients with BM. Similarly, in triple-negative breast cancer (TNBC), novel therapies such as sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) offer new hope for managing BM. For melanoma, the combination of immune checkpoint inhibitors such as nivolumab and ipilimumab has proven effective in enhancing survival for patients with BM, both in BRAF-mutant and wild-type cases. Developing targeted therapies penetrating the BBB has revolutionized BM treatment by targeting key drivers like EGFR, ALK, HER2, and BRAF. Despite improved survival, challenges persist, particularly for patients with resistant genetic alterations. Future research should optimise combination therapies, overcome resistance, and refine treatment sequencing. Continued emphasis on personalized, biomarker-driven approaches offers the potential to further improve outcomes, even for complex cases.

01 May 2025·EBioMedicine

A new EGFR and c-Met bispecific NIR-II fluorescent probe for visualising colorectal cancer and metastatic lymph nodes

Article

Author: Hu, Zhenhua ; Li, Changjian ; Wang, Yueqi ; Kong, Wenzhi ; Jin, Shangkun ; Wang, Yuhan ; Tian, Jie ; Tang, Jianqiang ; Jia, Xiaohua ; Quan, Jichuan ; Guo, Xiaoyong

BACKGROUND:

The aim of the study was to increase the specificity and targeting of tumour imaging, targeting molecules that enable the simultaneous recognition and binding of multiple tumour-associated receptors. We constructed a NIR-II fluorescence probe based on a bispecific antibody to epidermal growth factor receptor (EGFR) and cellular mesenchymal-epithelial transition factor (c-Met) for visualising colorectal cancers (CRCs) and metastatic lymph nodes.

METHODS:

The expression of EGFR and c-Met in tumour and metastatic lymph node specimens from patients with CRC was examined using immunohistochemistry. The EGFR and c-Met bispecific antibody (Rybrevant) was labelled, and its cell-specific binding ability was assessed using laser confocal microscopy. Subcutaneous CRC and orthotopic tumour models were constructed to evaluate the fluorescence imaging of the probe in vivo. To assess the performance of Rybrevant-IRDye800CW in the differential diagnosis of metastatic lymph nodes, a CRC lymph node metastasis model was constructed using human CRC cells implanted in mouse claw pads. Finally, surgically resected CRC tumours and lymph node specimens were incubated with Rybrevant-IRDye800CW for fluorescence NIR-II imaging to evaluate the efficacy of Rybrevant-IRDye800CW for preclinical visualisation.

FINDINGS:

The combined expression rate of EGFR and c-Met in CRC and metastatic lymph nodes was significantly higher than the single-target expression rate. The bispecific probe Rybrevant-IRDye800CW was successfully synthesised, and its fluorescence signal could be extended up to 1600 nm using NIR-II imaging. Cell incubation experiments showed that the fluorescence intensity of Rybrevant-IRDye800CW was strongly correlated with EGFR and c-Met overexpression of the cells. NIR-II in vivo fluorescence imaging showed that double-positively expressing subcutaneous tumours significantly uptook Rybrevant-IRDye800CW after tail vein injection of the probe, which rapidly accumulated within the tumours in about 6 h. In EGFR and or c-Met blockade assays, subcutaneous tumours showed weaker uptake of Rybrevant-IRDye800CW. Similarly, Rybrevant-IRDye800CW was specifically identified in orthotopic CRC and lymph node metastasis models, with all orthotopic tumours showing high tumour-to-background ratios in NIR-II imaging. In a NIR-II preclinical study, Rybrevant-IRDye800CW could specifically identify fresh human CRC and its metastatic lymph node tissue.

INTERPRETATION:

This study confirmed the complementary EGFR and c-Met expression in CRC and its metastatic lymph nodes. Compared to single-target probes, EGFR and c-Met dual-specific fluorescent probes identified CRC and its metastatic lymph nodes using NIR-II imaging. Thus, NIR-II-guided R0 surgery was performed to resect the CRC and metastatic lymph nodes.

FUNDINGS:

This study was supported by the Beijing Natural Science Foundation (Grant numbers: L222054, 7244517, 4232058, L248026, L232020), National Natural Science Foundation of China (NSFC) (92059207, 92359301, 92259303, 62027901, 81930053, 81227901, U21A20386), CAS Youth Interdisciplinary Team (JCTD-2021-08), and the Fundamental Research Funds for the Central Universities (Grant no. JK2024-2-35-02).

01 May 2025·LUNG CANCER

A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer

Article

Author: Li, Qiu ; Qin, Yi ; Wu, Qiuji

BACKGROUND:

The combination of amivantamab and lazertinib (AL) has demonstrated clinically significant efficacy in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, its economic value relative to the standard therapy, osimertinib, remains unclear. This study evaluates the cost-effectiveness of AL regimen compared with osimertinib in US and Chinese healthcare settings.

METHODS:

A partitioned survival model, comprising progression-free survival (PFS), post-progression, and death states, was developed using a Markov model. Clinical data were obtained from the recent Phase III MARIPOSA trial. Direct medical costs (including drug acquisition, administration, and adverse event management) were obtained from US and Chinese healthcare system data, public databases, and the literature. Health-state utilities were sourced from the literature. Incremental cost-effectiveness ratios (ICERs) were calculated based on quality-adjusted life years (QALYs). Threshold analysis was performed to identify pricing strategies at specified willingness-to-pay (WTP) thresholds. Model robustness was assessed through sensitivity and scenario analyses, and additional subgroup analyses performed.

RESULTS:

In the base case analysis, the average costs of AL and osimertinib regimen were $1,030,524.3 (China: $234,270.87) and $466,922.0 (China: $20,075.35), respectively, and the QALYs achieved were 4.08 (China: 3.66) and 2.60 (China: 2.66), respectively. The ICERs for AL compared with osimertinib in the US and China were $563,602.3 and $214,195.51, respectively. Based on the respective WTP thresholds in the US and China, the AL regimen did not represent a cost-effective option. Sensitivity, scenario, and subgroup analyses confirmed the robustness of these findings.

CONCLUSIONS:

Although AL regimen prolongs QALYs compared with osimertinib, it may not meet cost-effectiveness thresholds given current US pricing and simulated Chinese prices. These findings emphasize the need to consider policy implications and future pricing strategies.

251

News (Medical) associated with Amivantamab-VMJM

23 Apr 2025

·www.prnewswire.com

Taiho Oncology to Share Data in Five Presentations, Including Two Oral Presentations, at the 2025 American Society of Clinical Oncology Annual Meeting

Two oral presentations of phase 2 study findings from novel treatment options: an all-oral decitabine-cedazuridine combination for AML and zipalertinib for NSCLC that harbors exon 20 insertion mutations Additional presentations to include real-world data on the safety and effectiveness of two approved regimens: trifluridine-tipiracil paired with bevacizumab for metastatic colorectal cancer and futibatinib for cholangiocarcinoma PRINCETON, N.J., April 23, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today that it will present new data from five studies, including two oral presentations, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 through June 3 at McCormick Place in Chicago. The oral presentations will feature data regarding ASTX727 (oral decitabine-cedazuridine), an agent approved for myelodysplastic syndromes (MDS), paired with venetoclax for the treatment of acute myeloid leukemia (AML) and the novel investigational drug candidate zipalertinib for the treatment of non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The company will also share data on three real-world studies of two FDA-approved therapies: trifluridine and tipiracil paired with bevacizumab for the later-line treatment of adult patients with metastatic colorectal cancer and futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma. "ASCO provides an invaluable opportunity to bring together the leading minds in oncology and discuss emerging new therapies and our understanding of real-world outcomes of existing therapies," said Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology. "Our data at ASCO will continue to demonstrate our unwavering commitment to meaningful innovation that can potentially improve the lives of patients with cancer, their families and their caregivers." Details about these presentations can be found below: Oral Presentations Title: Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab Abstract Number: 8503 Session Name: Lung Cancer – Non-Small Cell Metastatic Session Type: Oral Abstract Session Session Date: June 1, 2025 Presentation Time: 8 a.m. – 11 a.m. CDT Location: Arie Crown Theater | Live Stream Presenter: Helena A. Yu, MD, Memorial Sloan Kettering Cancer Center Title: An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a Phase 2 cohort of 101 pts Abstract Number: 6504 Session Name: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Session Type: Oral Abstract Session Session Date: June 2, 2025 Presentation Time: 3 p.m. – 6 p.m. CDT Location: S100a | Live Stream Presenter: Amer Zeidan, MBBS, Yale Cancer Center Poster Presentation Title: Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer Abstract Number: 3580 Session Name: Gastrointestinal Cancer—Colorectal and Anal Session Type: Poster Presentation Session Date: May 31, 2025 Presentation Time: 9 a.m. – 12 p.m. CDT Location: Hall A - Posters and Exhibits | On Demand Presenter: Donald Richards, MD, PhD, of Texas Oncology Online Abstracts Title: Real-world Clinical Outcomes of Patients with Metastatic Colorectal Cancer (mCRC) Treated with Trifluridine-Tipiracil + Bevacizumab by Performance Status Abstract Number: E15606 Session Type: Publication Only Publication Date: May 22, 2025 Publication Time: 5 p.m. EDT Lead Author: Maliha Nusrat, MD, MS, Memorial Sloan Kettering Cancer Center Title: Real-World patient characteristics and treatment patterns among cholangiocarcinoma patients treated with FGFR inhibitors Abstract Number: E16262 Session Type: Publication Only Publication Date: May 22, 2025 Publication Time: 5 p.m. EDT Lead Author: Amit Mahipal, MD, University Hospitals Seidman Cancer Center and Case Comprehensive Cancer Center About Taiho Oncology, Inc. The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small-molecule clinical candidates targeting solid-tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company's European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada. For more information, visit , and follow us on LinkedIn and X. Taiho Oncology and the Taiho Oncology logo are registered trademarks of Otsuka Holdings Co., Ltd. or its subsidiaries. Taiho Oncology Contact: Leigh Labrie (609) 664-9878 [email protected] SOURCE Taiho Oncology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2ASCODrug ApprovalClinical Result

15 Apr 2025

·www.globenewswire.com

LiveWorld Releases First-Ever AI Brand Reputation Index for Leading Pharmaceutical Brands

Study Highlights Critical Influence of AI-Driven Reputation on Pharma Market Leaders and New EntrantsCAMPBELL, Calif. and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), a pioneer in social-first digital engagement and integrated human-AI solutions, today released its inaugural AI Brand Reputation Index, providing unprecedented insight into how artificial intelligence shapes the perceptions of 50 leading pharmaceutical brands. The comprehensive study identifies key reputation drivers, revealing crucial implications for market leaders and emerging therapies alike. "As healthcare professionals, patients, and caregivers increasingly rely on AI-driven platforms for information, pharmaceutical brands must understand and actively manage their AI-driven reputations," said Peter Friedman, LiveWorld Chairman and CEO. "This index gives companies actionable insights to strategically enhance their brand positioning and ensure long-term success." Key Findings from the Report Include: Market Leaders Confirmed: Brands with high consumer familiarity and proven efficacy, such as Dupixent, and Keytruda, demonstrated robust AI reputations, driven by clinical effectiveness and healthcare professional trust.Advertising Not the Only Driver: Vertex Pharmaceuticals' Trikafta topped the rankings despite limited advertising, showcasing the power of clinical efficacy, healthcare provider endorsement, and authentic patient advocacy in building AI-driven brand perception.Challenges for New Therapies: Emerging drugs like Leqvio and Rybrevant struggle with AI visibility, highlighting immediate opportunities for strategic content marketing.Safety Perceptions Persist: Products with perceived safety concerns, such as Remicade and Xeljanz, face significant hurdles in AI-driven reputation, underscoring the lasting impact of safety profiles.Accessibility Matters: Brands recognized for affordability and patient-friendly access, including Farxiga and Jardiance, enjoyed enhanced AI-driven sentiment. The study utilizes LiveWorld’s proprietary AI framework assessing seven weighted reputation factors across prominent large language models (LLMs) including ChatGPT (GPT-4), Perplexity, and Grok. These factors encompassed efficacy, safety, healthcare professional trust, consumer sentiment, digital visibility, affordability, and patient loyalty. Based on the rankings, the study recommends strategic approaches for pharma companies to build up their brand reputation starting with investing in AI-powered brand monitoring and continuous reputation management. "AI-driven reputation management is no longer optional—it is a strategic imperative," added Friedman. "Brands that proactively engage with their AI presence will significantly outperform their competition." Helpful Links: LiveWorld AI Brand Reputation Index for Pharma Top 50 BrandsBrands interested in requesting a customized AI brand reputation report for their brand with competitive comparisons may contact us here. About LiveWorld LiveWorld is a social-first digital agency and software company that unlocks the full potential of social media to transform customer relationships through integrated compliance, engagement, and insight solutions. We provide brand marketers bold creative rooted in strategy that captivates and resonates, social moderation and engagement that activates interactions, software that enriches customer experiences, and compliance that enables and accelerates digital programs. With over 28 years of making connections, we leverage our social media DNA to deliver emotion-driven behavior change through digital campaigns with a human touch. LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld. LiveWorld ContactPR Contact:Matthew HammerLiveWorldmhammer@liveworld.com(737) 212-9739

15 Apr 2025

·www.biopharmadive.com

J&J keeps forecasts steady as pharma confronts tariff threat

Johnson & Johnson is confident it can manage the impact of tariffs on its pharmaceuticals and medical device businesses this year, announcing Tuesday that it will maintain its financial forecast for the year while raising its sales guidance.J&J, which is the first large drugmaker to report results for the first quarter, expects adjusted earnings per share of $10.60 for 2025. That number is the same as the company estimated in January, before President Donald Trump announced sweeping new tariff policies that will tax imports of medical devices along with most other goods.Duties on drugs are likely coming soon, too. The Trump administration disclosed Monday an investigation into the national security effects of pharmaceutical imports in a move that analysts anticipate will result in new levies in the near future.We built into our guidance about $400 million in tariff costs based on what we know today, said J&J CFO Joe Wolk in a CNBC interview Tuesday morning. It was really a pretty healthy beat considering we didnt have those things in January that were now absorbing.Much of that $400 million impact involves J&Js medical device business, Wolk clarified on a company conference call held later on Tuesday morning, and also reflects retaliatory tariffs China has imposed on U.S. goods.Wolk declined to share an annualized estimate for the impact of tariffs, citing the fast-changing nature of the Trump administrations policies.Yet, for an industry shaken by both Trumps tariff threat and a chaotic regulatory restructuring, J&Js stability may be welcome news.[J&J management] downplayed tariff risks this morning, which we view as an important positive development for perception about the threat to [J&J] and the branded biopharma industry at large, wrote Leerink Partners analyst David Risinger in a client note.Recently, J&J said it will spend $55 billion over the next four years on building new drug factories in the U.S., one of several drugmaker announcements of plans to reshore manufacturing to the U.S. something Trump has leaned specifically on the industry to do. After those plants are complete, J&J expects that essentially all of its advanced medicines will be made in the U.S.Speaking on the companys conference call, J&J CEO Joaquin Duato made the case that tax policy, not tariffs, is more effective at spurring capital investment.Tariffs can create disruptions in the supply chain, leading to shortages, Duato said. If what you want is to build manufacturing capacity in the U.S. ... the most effective answer is not tariffs, but tax policy.The pharmaceutical industry benefited mightily from the tax law passed in 2017 during Trumps first administration, and is arguing for its renewal.Its unclear what kind of pharma tariffs might emerge from the newly begun probe by the Department of Commerce. According to a regulatory notice posted Monday, Commerce will look at both branded and generic medicines, as well as the active drug ingredients they contain and the starting materials from which theyre derived.Trump has threatened duties between 50% and 200%, which, if imposed, would dramatically increase costs for an industry that has supply chains spread throughout Europe and Asia. Most precursor chemicals and active ingredients are sourced from China and India, while many branded manufacturers have production facilities in countries like Ireland, Switzerland, the Netherlands and Singapore.Wolk, in his CNBC interview, speculated that the administration might focus on generic medicines and precursor chemicals, but stressed that was only J&Js view of where national security concerns might be most acute.I think its also important that companies in healthcare partner with the administration to look to mitigate some of the vulnerabilities that exist today in other healthcare supply chains, said Duato, on the conference call. It is important for us to partner with the administration ... and we plan to do it.Overall, J&J reported sales of about $21.9 billion during the first three months of the year, an increase of 2.4% from the same period the year prior and higher than consensus Wall Street estimates. Revenue from the companys pharma business also beat expectations, totaling roughly $13.9 billion in the quarter.J&J executives highlighted on the call several of the companys approved medicines and two experimental therapies for which it thinks analysts forecasts are too low. Notably, the company expects sales of its cancer drug combination Rybrevant and Lazcluze to reach about twice as high in 2027 as Wall Streets current estimate of $1.8 billion.Shares were trading down about 0.5% by mid-morning Tuesday. '

100 Deals associated with Amivantamab-VMJM

External Link

KEGG	Wiki	ATC	Drug Bank
-	Amivantamab-VMJM	L01	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
EGFR positive non-small cell lung cancer	Japan	Janssen Pharmaceutical KK	27 Mar 2025
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer	United States	Janssen Biotech, Inc.	19 Aug 2024
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer	United States	Janssen Biotech, Inc.	19 Aug 2024
Non-Small Cell Lung Cancer	Canada	Janssen, Inc.	30 Mar 2022
EGFR ex20ins mutation in non-small cell lung cancer	United States	Janssen Biotech, Inc.	21 May 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	China	Janssen-Cilag International NV	26 Jan 2024
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	China	Shanghai Johnson & Johnson Pharmaceutical Ltd.	26 Jan 2024
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	China	Cilag AG	26 Jan 2024
Colorectal Cancer	Phase 3	United States	Janssen Research & Development LLC	12 Dec 2024
Colorectal Cancer	Phase 3	China	Janssen Research & Development LLC	12 Dec 2024
Colorectal Cancer	Phase 3	Japan	Janssen Research & Development LLC	12 Dec 2024
Colorectal Cancer	Phase 3	Australia	Janssen Research & Development LLC	12 Dec 2024
Colorectal Cancer	Phase 3	Belgium	Janssen Research & Development LLC	12 Dec 2024
Colorectal Cancer	Phase 3	Brazil	Janssen Research & Development LLC	12 Dec 2024
Colorectal Cancer	Phase 3	France	Janssen Research & Development LLC	12 Dec 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04988295 (MARIPOSA-2, CTgov)	Phase 3	EGFR-mutated non-small Cell Lung Cancer	776	ACP-L+Amivantamab+Carboplatin+Pemetrexed+Lazertinib (Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L))	rilsqufxfm(fbfmnnjiff) = gfjctofqlt vzdlqlnypf (jizzdllaud, zlfqxjotoz - natngwsgim) View more	-	16 Apr 2025
				Carboplatin+Pemetrexed (CP) (Main Study: Arm B: Carboplatin + Pemetrexed (CP))	rilsqufxfm(fbfmnnjiff) = pmsprszive vzdlqlnypf (jizzdllaud, yixlpoqpre - pqtaipgxaz) View more
NCT06120140 (COCOON, ESMO_ELCC2025)	Phase 2	EGFR-mutated non-small Cell Lung Cancer First line Ex19del/L858R	200	amivantamab (Enhanced Dermatologic Management (COCOON DM))	kpheosncej(eimcpqwneh) = oqebkmcfyk yzkbydftyc (dphmlijwoa ) View more	Positive	27 Mar 2025
				amivantamab (Standard of Care Dermatologic Management (SoC DM))	kpheosncej(eimcpqwneh) = miwaynvcpo yzkbydftyc (dphmlijwoa ) View more
NCT04487080 (MARIPOSA, ESMO_ELCC2025) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer First line EGFR L858R \| EGFR Exon 19 Deletion	-	Amivantamab plus Lazertinib	zwswaxvvpd(zwvqiwplsg) = zvrrkukkld nsbxiwddbq (hlxbgwebfs, 42.9 - NE) View more	Positive	26 Mar 2025
				Osimertinib	zwswaxvvpd(zwvqiwplsg) = isppnogtpb nsbxiwddbq (hlxbgwebfs, 33.4 - 41.0) View more
NCT04077463 (CHRYSALIS-2, ESMO_ELCC2025) Manual	Phase 1	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	49	Amivantamab plus Lazertinib	zppwwprwad(azidwflpch) = aqynvbakqs hrjuewalif (ruzziugude ) View more	Positive	26 Mar 2025
				EGFR TKIs (Osimertinib, Afatinib)	zppwwprwad(azidwflpch) = ptxdlqylyy hrjuewalif (ruzziugude ) View more
ATLAS (ESMO_ELCC2025)	Not Applicable	EGFR Exon 20 insertion mutations	64	Amivantamab	rpovjubjyq(axnmzuwkwk) = 53.1% with G33 in 7.8% prauhalhmp (cnwxcxezvu ) View more	Positive	26 Mar 2025
NCT05498428 (PALOMA-2, ESMO_ELCC2025)	Phase 2	Non-Small Cell Lung Cancer EGFRm \| MET-related	25	IV Amivantamab	qhhttesbpe(nmiogmnruc) = Most adverse events (AEs) were EGFR/MET-related and grade 1-2. Most common AEs were paronychia (44%; gr≥3: 4%), rash-related (40%; gr≥3: 12%), and hypoalbuminemia (40%; gr≥3: 4%). No ARRs were reported; 1 pt discontinued ami due to a treatment-related AE (interstitial lung disease) djznfqdnmm (disrugsubm ) View more	Positive	26 Mar 2025
				SC Amivantamab
NCT05379595 (OrigAMI-1, ASCO_GI2025) Manual	Phase 1/2	Metastatic Colorectal Carcinoma	30	Amivantamab monotherapy	rxupzuzsno(phxidzslkz) = ptzzomnkfj vdnbozdxyc (fmzlzqdpjv, 56 - 93) View more	Positive	23 Jan 2025
				Amivantamab + FOLFOX or FOLFIRI	rxupzuzsno(phxidzslkz) = bbjkvudfxt vdnbozdxyc (fmzlzqdpjv, 42 - 100) View more
NCT04487080 (MARIPOSA, Company_Website) Manual	Phase 3	Non-Small Cell Lung Cancer First line EGFR Exon 19 Deletion \| EGFR L858R	1,074	RYBREVANT+LAZCLUZE	ucxiyynwfb(qayiaiggmp) = clinically meaningful and statistically significant improvement in OS versus the current standard of care osimertinib. Improvement in median OS is expected to exceed one year. bfiqvflyxx (sajsbciplg ) Met	Positive	07 Jan 2025
				osimertinib
NCT04077463 (CHRYSALIS-2, Pubmed) Manual	Phase 1	EGFR-mutated non-small Cell Lung Cancer EGFR L858R \| EGFR Exon 19 Deletion	162	Amivantamab 1050 mg + Lazertinib 240 mg	suynusmdcf(glrdmakzsy) = yblpxhhfxb hrlgjpquoz (ekssqsyqlv, 22 - 36) View more	Positive	02 Jan 2025
NCT02609776 (CHRYSALIS, ESMO_ASIA2024) Manual	Not Applicable	Non-Small Cell Lung Cancer EGFR Exon 20 Insertion	114	Amivantamab	ohaclfkmqd(onfsrhkruh) = jvigxuevfh vblzbkjibw (wectommuvd ) View more	Positive	07 Dec 2024
				External control（Taiwan real-world setting）	ohaclfkmqd(onfsrhkruh) = mgixcirvlc vblzbkjibw (wectommuvd ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis